Metagenomi Inc. (MGX) - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti

Metagenomi, Inc - MGX emitenti grafik logotipi

Quyida aks etgan va ko'rsatkich -0.30 darajasida bo'lgan narxlar tendentsiyasi Metagenomi, Inc. (MGX) kompaniyasining patent cheklovlarini chetlab o'tuvchi innovatsion gen tahrirlash vositalarini ishlab chiqish uchun metagenomik tahlildan foydalanishiga asoslangan. Yuqori R&D xarajatlari va qat'iy tartibga soluvchi nazorat biznes uchun mustahkam himoya to'sig'ini yaratadi. Hozirda savdo hajmi mavjud emasligiga qaramay, Metagenomi, Inc. (MGX) noyob genetik patologiya terapiyasi segmentida ulkan narx belgilash imkoniyatiga ega.

MGX Metagenomi Inc.: Narxning foydaga nisbati 16.08.2024 - 16.11.2026 oraligʻida

Metagenomi, Inc. kompaniyasining tahliliy kesimlari

- narx va narxlar bo'yicha konsensus prognoz:
- bozor kapitallashuvi ko'rsatkichlari:
Kompaniyaning jamlanma tahlili:Metagenomi, Inc.
Metagenomi, Inc. original mahsuloti

P/E koeffitsiyenti sof foydaning bir birligining bozor qiymatini aks ettiradi, bu esa investorlarga aktivning haddan tashqari qimmat baholanganini yoki ular qiymat tuzog'iga duch kelayotganini baholash imkonini beradi. Kompaniyaning P/E darajasini tahlil qilish orqali investor bozor kapitalizatsiyasining foydaga nisbatini aniqlashi mumkin, bu esa geosiyosiy xatarlarsiz AQShda yetakchi klinikadan oldingi tadqiqotlarni olib borayotgan Metagenomi, Inc. (MGX) uchun DNK tahrirlashdagi kelajakdagi texnologik yutuqlarning investitsiya qiymatini ta'kidlaydi.

Raqobatdosh kompaniyalar

tempus.com - Kapitalizatsiyaning sof foydaga nisbati|P/E multiplikatori QGEN|Biznesning o‘zini qoplash muddati Isis Pharmaceuticals|P/E multiplikatori RGEN (repligen.com)|Bozor narxining sof foydaga nisbati RNA (Avidity Biosciences, Inc.)|CRSP - Narxning foydaga nisbati|Kompaniya qiymatining sof foydaga nisbati WGS (GeneDx)|RARE: P/E multiplikatori|Beam Therapeutics Corp - Kompaniya qiymatining sof foydaga nisbati|Narx-foyda koeffitsiyenti SRPT|twistbioscience.com (TWST) - Biznesning o‘zini qoplash muddati|P/E multiplikatori TXG|NTLA (Intellia) - Kompaniya qiymatining sof foydaga nisbati|Narxning foydaga nisbati Stoke STOK|BioLife (BLFS) - Kapitalizatsiyaning foydaga nisbati|wavelifesciences.com - P/E multiplikatori|Kapitalizatsiyaning sof foydaga nisbati MAZE|SION: P/E multiplikatori|PRME - Biznesning o‘zini qoplash muddati|Narx-foyda koeffitsiyenti TSHA|QURE - Kapitalizatsiyaning sof foydaga nisbati koeffitsiyenti|P/E multiplikatori MGTX|Biznesning o‘zini qoplash muddati regenxbio.com|P/E multiplikatori SLDB (Solid Biosciences Inc)|OCGN: Narx-foyda multiplikatori|PACB - Narxning foydaga nisbati|Benitec (BNTC) - Narx-foyda koeffitsiyenti|DSGN: P/E multiplikatori|RCKT: Bozor narxining sof foydaga nisbati|FDMT (4D Molecular Therapeutics, Inc.) - P/E multiplikatori|lexeotx.com (LXEO) - Biznesning o‘zini qoplash muddati|P/E multiplikatori KRRO|Narx-foyda koeffitsiyenti Editas Medicine, Inc. EDIT|Narxning foydaga nisbati silence-therapeutics.com SLN|PRQR: Narx-foyda multiplikatori|CDXS - Narxning foydaga nisbati|Biznesning o‘zini qoplash muddati Sangamo Therapeutics, Inc. SGMO|NAUT (nautilus.bio) - Narx-foyda koeffitsiyenti|Narx-foyda multiplikatori DTIL|GBIO (Generation Bio) - P/E multiplikatori|Narx-foyda multiplikatori BOLD (boundlessbio.com)|Narx-foyda koeffitsiyenti XCUR (exicuretx.com)|Celsion Corporation - Narx-foyda multiplikatori|P/E multiplikatori PHIO (phiopharma.com)|P/E multiplikatori Mustang Bio, Inc. MBIO|RNAZ: Narx-foyda koeffitsiyenti|BNGO (Bionano Genomics) - Narx-foyda multiplikatori|APDN: P/E multiplikatori|bluebird bio (BLUE) - P/E multiplikatori|Narxning foydaga nisbati ImmunoPrecise Antibodies Ltd.|Kapitalizatsiyaning foydaga nisbati Omega OMGA|P/E multiplikatori OMIC|RGLS - Kapitalizatsiyaning foydaga nisbati|Syros Pharmaceuticals, Inc - Narx-foyda koeffitsiyenti|Biznesning o‘zini qoplash muddati Codex DNA (TBIO)|TCON - Narxning foydaga nisbati|UBX: Narxning foydaga nisbati